Genomics of cervical cancer and the role of human papillomavirus pathobiology

Clinical Chemistry

Volumn 60, Issue 1, 2014, Pages 144-146

  Uyar, Denise ^a   Rader, Janet ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CANCER VACCINE; CISPLATIN; DNA METHYLTRANSFERASE; ONCOPROTEIN; TOPOTECAN; VIRUS DNA;

ARTICLE; CANCER SCREENING; CARCINOGENESIS; CELL CYCLE REGULATION; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; DNA METHYLATION; GENE OVEREXPRESSION; GENOMICS; HUMAN; IMMUNOLOGICAL TOLERANCE; INFECTION PREVENTION; MALIGNANT TRANSFORMATION; MOLECULAR IMAGING; NONHUMAN; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PERSISTENT INFECTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL STATUS; TUMOR INVASION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX DYSPLASIA; VIRUS CELL INTERACTION; WART VIRUS;

EID: 84891821548     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2013.212985     Document Type: Article

References (15)

1. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012;30 Suppl 5:F12-23.
2. Wright JD, Li J, Gerhard DS, Zhang Z, Huettner PC, Powell MA, et al. Human papillomavirus type and tobacco use as predictors of survival in early stage cervical carcinoma. Gynecol Oncol 2005;98: 84-91. (Pubitemid 40826423)
3. Fragoso-Ontiveros V, Maria Alvarez-Garcia R, Contreras-Paredes A, Vaca-Paniagua F, Alonso Herrera L, Lopez-Camarillo C, et al. Gene expression profiles induced by E6 from non-European HPV18 variants reveals a differential activation on cellular processes driving to carcinogenesis. Virology 2012;432: 81-90.
4. Contreras-Paredes A, De la Cruz-Hernandez E, Martinez-Ramirez I, Duenas-Gonzalez A, Lizano M. E6 variants of human papillomavirus 18 differentially modulate the protein kinase B/phosphatidylinositol 3-kinase (Akt/PI3K) signaling pathway. Virology 2009;383: 78-85.
5. Rader J. Host and viral genetics and risk of cervical cancer. In: Welsch P, ed. The role of genetics in breast and reproductive cancers. New York: Springer; 2009. p 263-84.
6. Schmitz M, Driesch C, Beer-Grondke K, Jansen L, Runnebaum IB, Durst M. Loss of gene function as a consequence of human papillomavirus DNA integration. Int J Cancer 2012;131:E593-602.
7. Snellenberg S, Schutze DM, Claassen-Kramer D, Meijer CJ, Snijders PJ, Steenbergen RD. Methylation status of the E2 binding sites of HPV16 in cervical lesions determined with the Luminex- xMAP™ system. Virology 2012;422: 357-65.
8. Jordanova ES, Gorter A, Ayachi O, Prins F, Durrant LG, Kenter GG, et al. Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8-/regulatory T-cell ratio: Which variable determines survival of cervical cancer patients? Clin Cancer Res 2008;14: 2028-35.
9. Chen D, Juko-Pecirep I, Hammer J, Ivansson E, Enroth S, Gustavsson I, et al. Genome-wide association study of susceptibility loci for cervical cancer. J Natl Cancer Inst 2013;105: 624-33.
10. Wang SS, Gonzalez P, Yu K, Porras C, Li Q, Safaeian M, et al. Common genetic variants and risk for HPV persistence and progression to cervical cancer. PLoS One 2010;5:e8667.
11. Lu Q, Ma D, Zhao S. DNA methylation changes in cervical cancers. Methods Mol Biol 2012;863: 155-76.
12. Kidd EA, El Naqa I, Siegel BA, Dehdashti F, Grigsby PW. FDG-PET-based prognostic nomograms for locally advanced cervical cancer. Gynecol Oncol 2012;127: 136-40.
13. Zighelboim I, Wright JD, Gao F, Case AS, Massad LS, Mutch DG, et al. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol 2013;130: 64-8.
14. Schwarz JK, Payton JE, Rashmi R, Xiang T, Jia Y, Huettner P, et al. Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer. Clin Cancer Res 2012;18: 1464-71.
15. Schwarz JK, Lewis JS Jr, Pfeifer J, Huettner P, Grigsby P. Prognostic significance of p16 expression in advanced cervical cancer treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 2012;84: 153-7.